Piris-Villaespesa, M. and Alvarez-Twose, I. (2020) ‘Systemic mastocytosis: Following the tyrosine kinase inhibition roadmap’, Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.00443.

Gotlib, J. et al. (2022) ‘Proposed European Competence Network on mastocytosis—American initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis’, The Journal of Allergy and Clinical Immunology: In Practice, 10(8). https://doi.org/10.1016/j.jaip.2022.05.034.

Choi JK, et al. Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: Acute lymphoblastic leukemias, mixed-phenotype acute leukemias, myeloid/lymphoid neoplasms with eosinophilia, dendritic/histiocytic neoplasms, and genetic tumor syndromes. Mod Pathol. 2024;37(5):100466. https://doi.org/10.1016/j.modpat.2024.100466.

Article  PubMed  Google Scholar 

Akin C. Tyrosine kinase inhibitors in non-advanced systemic mastocytosis. Immunol Allergy Clin North Am. 2023;43(4):743–50. https://doi.org/10.1016/j.iac.2023.05.001.

Article  PubMed  Google Scholar 

Mesa RA, et al. Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the touchstone SM patient survey. Cancer. 2022;128(20):3691–9. https://doi.org/10.1002/cncr.34420.

Article  PubMed  Google Scholar 

Buonomo, A., Nucera, E. and Criscuolo, M. (2022) ‘Treatment of indolent and advanced systemic mastocytosis’, Mediterranean Journal of Hematology and Infectious Diseases, 14(1). https://doi.org/10.4084/mjhid.2022.040.

Leone A, et al. Systemic mastocytosis revisited with an emphasis on skeletal manifestations. Radiol Med (Torino). 2020;126(4):585–98. https://doi.org/10.1007/s11547-020-01306-8.

Article  PubMed  Google Scholar 

Leguit RJ, et al. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2022;482(1):99–112. https://doi.org/10.1007/s00428-022-03423-3.

Article  CAS  PubMed  Google Scholar 

Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508–25. https://doi.org/10.1002/ajh.26118.

Article  PubMed  Google Scholar 

Hermans MAW, et al. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre. Eur J Intern Med. 2016;30:25–30. https://doi.org/10.1016/j.ejim.2016.01.005.

Article  PubMed  Google Scholar 

Cohen SS, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521–8. https://doi.org/10.1111/bjh.12916.

Article  PubMed  Google Scholar 

Lübke, J. et al. (2024) ‘Serum chemistry profiling and prognostication in systemic mastocytosis: A registry-based study of the ECNM and Grem’, Blood Advances [Preprint]. https://doi.org/10.1182/bloodadvances.2024012756.

Sánchez-Muñoz L, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: A Spanish network on mastocytosis (rema) study on 122 patients. Br J Haematol. 2015;172(1):56–63. https://doi.org/10.1111/bjh.13789.

Article  PubMed  Google Scholar 

Schwartz LB, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. Journal of Clinical Investigation. 1995;96:2702–10. https://doi.org/10.1172/jci118337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and Management. Am J Hematol. 2023;98(8):1307–25. https://doi.org/10.1002/ajh.26984.

Article  CAS  PubMed  Google Scholar 

Wang SA, et al. The international consensus classification of Eosinophilic Disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286–306. https://doi.org/10.1002/ajh.26966.

Article  CAS  PubMed  Google Scholar 

Zanotti R, et al. Bone marrow mastocytosis: A diagnostic challenge. J Clin Med. 2021;10(7):1420. https://doi.org/10.3390/jcm10071420.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pardanani A, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769–72. https://doi.org/10.1182/blood-2009-05-220145.

Article  CAS  PubMed  Google Scholar 

Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023;98(7):1097–116. https://doi.org/10.1002/ajh.26962.

Article  CAS  PubMed  Google Scholar 

Lim K-H, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood. 2009;113(23):5727–36. https://doi.org/10.1182/blood-2009-02-205237.

Article  CAS  PubMed  Google Scholar 

Jawhar M, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with Kit D816V+ advanced systemic mastocytosis. Blood. 2015;126(23):349–349. https://doi.org/10.1182/blood.v126.23.349.349.

Article  Google Scholar 

Jawhar M, et al. Mars: Mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37(31):2846–56. https://doi.org/10.1200/jco.19.00640.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muñoz-González, J.I. et al. (2021) ‘Proposed global prognostic score for systemic mastocytosis: A retrospective prognostic modelling study’, The Lancet Haematology, 8(3). https://doi.org/10.1016/s2352-3026(20)30400-2.

Valent, P. et al. (2022) ‘Personalized management strategies in mast cell disorders: ECNM-AIM User’s guide for Daily Clinical Practice’, The Journal of Allergy and Clinical Immunology: In Practice, 10(8). https://doi.org/10.1016/j.jaip.2022.03.007.

Akin C. Anaphylaxis and mast cell disease: What is the risk? Curr Allergy Asthma Rep. 2010;10(1):34–8. https://doi.org/10.1007/s11882-009-0080-8.

Article  CAS  PubMed  Google Scholar 

Gülen T. A puzzling mast cell trilogy: Anaphylaxis, MCAS, and mastocytosis. Diagnostics. 2023;13(21):3307. https://doi.org/10.3390/diagnostics13213307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niedoszytko M, et al. Mastocytosis and insect venom allergy: Diagnosis, safety and efficacy of Venom immunotherapy. Allergy. 2009;64(9):1237–45. https://doi.org/10.1111/j.1398-9995.2009.02118.x.

Article  CAS  PubMed  Google Scholar 

Broesby-Olsen S, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy. 2017;73(1):230–8. https://doi.org/10.1111/all.13237.

Article  CAS  PubMed  Google Scholar 

Farmer, I. et al. (2024) ‘Prevalence of reduced bone mineral density in indolent systemic mastocytosis: UK single-centre retrospective review’ BSH24-PO32. https://doi.org/10.1111/bjh.19398

Makovoz, A. et al. (2021) ‘Assessment of osteoporosis and fracture risk in mastocytosis within a North American cohort’, The Journal of Allergy and Clinical Immunology: In Practice, 9(12). https://doi.org/10.1016/j.jaip.2021.08.001.

Lim KH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, Imatinib Mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84(12):790–4. https://doi.org/10.1002/ajh.21561.

Article  CAS  PubMed  Google Scholar 

Barete S, et al. Long-term efficacy and safety of Cladribine (2-CDA) in adult patients with mastocytosis. Blood. 2015;126(8):1009–16. https://doi.org/10.1182/blood-2014-12-614743.

Article  CAS  PubMed  Google Scholar 

Arun, V.A. et al. (2021) ‘Aggressive systemic mastocytosis presenting as rapidly progressive ascites, generalised lymphadenopathy and osteosclerosis’, BMJ Case Reports, 14(2). https://doi.org/10.1136/bcr-2020-238034.

Ferrari, J. et al. (2022) ‘Mastocytosis: Fertility and pregnancy management in a rare disease’, Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.874178.

Alvarez-Twose I, et al. Imatinib in systemic mastocytosis: A phase IV clinical trial in patients lacking exon 17 kit mutations and review of the literature. Oncotarget. 2016;8(40):68950–63. https://doi.org/10.18632/oncotarget.10711.

Article  PubMed  PubMed Central  Google Scholar 

Lortholary O, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study. The Lancet. 2017;389(10069):612–20. https://doi.org/10.1016/s0140-6736(16)31403-9.

Article  CAS  Google Scholar 

Gotlib J, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530–41. https://doi.org/10.1056/nejmoa1513098.

Article  CAS